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Abstract
Purpose: screening tool of older people’s prescriptions (STOPP) and screening tool to alert to right treatment (START) cri-
teria were ﬁrst published in 2008. Due to an expanding therapeutics evidence base, updating of the criteria was required.
Methods: we reviewed the 2008 STOPP/START criteria to add new evidence-based criteria and remove any obsolete criteria.
A thorough literature review was performed to reassess the evidence base of the 2008 criteria and the proposed new criteria.
Nineteen experts from 13 European countries reviewed a new draft of STOPP & START criteria including proposed new cri-
teria. These experts were also asked to propose additional criteria they considered important to include in the revised STOPP
& START criteria and to highlight any criteria from the 2008 list they considered less important or lacking an evidence base.
The revised list of criteria was then validated using the Delphi consensus methodology.
Results: the expert panel agreed a ﬁnal list of 114 criteria after two Delphi validation rounds, i.e. 80 STOPP criteria and 34
START criteria. This represents an overall 31% increase in STOPP/START criteria compared with version 1. Several new
STOPP categories were created in version 2, namely antiplatelet/anticoagulant drugs, drugs affecting, or affected by, renal
function and drugs that increase anticholinergic burden; new START categories include urogenital system drugs, analgesics
and vaccines.
Conclusion: STOPP/START version 2 criteria have been expanded and updated for the purpose of minimizing inappropriate
prescribing in older people. These criteria are based on an up-to-date literature review and consensus validation among a
European panel of experts.
Keywords: inappropriate prescribing, older people, STOPP/START criteria
Introduction
Adverse drug reactions (ADRs) in older people currently re-
present a serious and growing public health problem [1].
Polypharmacy and inappropriate prescribing (IP) are well-
known risk factors for ADRs, which commonly cause adverse
clinical outcomes in older people [2, 3]. IP encompasses po-
tentially inappropriate medications (PIMs) and potential pre-
scribing omissions (PPOs) [4]. STOPP/START criteria for
potential IP in older people recognise the dual nature of IP by
including a list of PIMs (STOPP criteria) and PPOs (START
criteria). Since the ﬁrst iteration of STOPP/START criteria in
2008 [5], our research group has shown a number of import-
ant properties of STOPP/START criteria, namely:
• STOPP criteria medications are signiﬁcantly associated
with adverse drug events (ADEs), unlike Beers 2003 cri-
teria medications [6].
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• STOPP/START criteria as an intervention applied at a
single time point during hospitalisation for acute illness in
older people signiﬁcantly improve medication appropriate-
ness [7], an effect that is maintained 6 months post-
intervention.
• STOPP/START criteria as an intervention applied within
72 h of admission signiﬁcantly reduce ADRs (with an abso-
lute risk reduction of 9.3%; number needed to treat = 11)
and average length of stay by 3 days in older people hospita-
lised with unselected acute illnesses [8, https://
www.clinicaltrials.gov/ct2/show/study/NCT01467050, 19
June 2014, date last accessed]).
For these reasons, we contend that STOPP/START cri-
teria have practical clinical value. Although these ﬁndings are
recent, it has become clear that an updated version of
STOPP/START criteria is required due to a changing evi-
dence base underpinning the ﬁrst version of STOPP/
START, the licensing of important new drugs since 2008
and the recognition of a more extensive list of PIMs than
had been included in version 1. In addition, a number of
STOPP/START criteria were no longer considered com-
pletely accurate or relevant, e.g. the use of calcium channel
blockers (of any kind) in patients with chronic constipation
(STOPP criterion) and the use of aspirin for primary preven-
tion of cardiovascular disease in patients with diabetes
(START criterion). It was also clear that a small number (12
in total) of criteria in STOPP/START version 1 were lacking
in clinical importance or prevalence and were therefore of
less relevance compared with other criteria in the list. In add-
ition, there were some important criteria that were absent
from STOPP/START version 1. Finally, we considered that
STOPP/START criteria would be enhanced by seeking the
input of a wider ranging panel of experts from across Europe
than the panel of Irish and UK experts involved in the valid-
ation of version 1; this was to reﬂect Europe-wide prescribing
practices in the general population of older people.
The aim of this study was to prepare and validate a new
version of STOPP/START criteria so as to reﬂect more
complete and up-to-date sets of PIMs and PPOs that may
have serious negative effects on the health and well-being of
older people in most clinical settings.
Methods
We proposed new criteria to be added to the 2008 list of
STOPP/START criteria on the basis of an expanded evi-
dence base since 2008. We evaluated these proposed new
criteria in terms of their clinical importance, accuracy and evi-
dence base. If the proposed new criteria met these require-
ments, we included them in the ﬁrst draft of the STOPP/
START version 2 criteria for further validation.
We recruited a panel of 19 experts from 13 countries in
Europe, who had recognised expertise in Geriatric
Medicine and pharmacotherapy in older people. We asked
each expert to comment on the 2008 STOPP/START cri-
teria, in particular their opinions on their current validity
and relevance. We asked the expert panel members to
propose additional STOPP and START criteria and ways to
improve the structure and content of the existing criteria.
We evaluated all new criteria proposed by the expert panel
in terms of their clinical importance, accuracy and evidence
base.
We then undertook a process of establishment of the
evidence base to support all proposed criteria, including
both the criteria to be retained from STOPP/START
version 1 and also the suggested additional criteria. The
STOPP/START version 1 criteria were reviewed in terms
of the current evidence base to support them. Some of the
version 1 criteria were found to lack a ﬁrm evidence base, e.
g. statin therapy for primary prevention of cardiovascular
disease in diabetes mellitus. The authors proposed some
new criteria, as did the expert panel members. We then
searched PubMed, Embase and Cochrane Library data-
bases for recent published evidence to underpin each
version 1 criterion and the proposed new criteria. The key
search words relating to each proposed criterion were
entered in the three databases and relevant articles identi-
ﬁed in the categories: systematic reviews, randomised con-
trolled trials (RCTs) and reviews. In addition, we examined
other sources, such as recently published textbooks, the
British National Formulary and NICE (http://www.nice.
org.uk/) and SIGN (http://www.sign.ac.uk/guidelines/
published/numlist.html, 1 March 2014, date last accessed)
treatment guidelines for sources of references. Where we
did not ﬁnd systematic reviews to support a particular cri-
terion, we searched for reviews or RCTs that indicated
clearly that the criterion was evidence based and therefore
appropriate to include in STOPP/START version 2. Three
members of the research team (the principal author and
two postgraduate students under the principal author’s
supervision) read the selected articles to ensure their suit-
ability as support evidence. From the initial list of proposed
criteria, we removed criteria that did not have a clear evi-
dence base. The remaining proposed criteria were organised
according to physiological systems for further consensus as-
sessment by the expert panel.
We then made available all of the relevant reference
articles that constituted the support reference bank for the
STOPP/START version 2 draft criteria to the members of
the expert panel; we provided the latter in an online reference
paper repository, using DropBox® software. The Delphi
panel members were offered the abstracts and full publica-
tion versions of all of the selected articles relating to each
proposed criterion. Each of the selected articles provided an
evidence base to support each proposed criterion, and it was
left to the discretion/need of each Delphi panel member to
assess the evidence presented from the selected articles pro-
vided by the literature search. We did not ask the Delphi
panel members to read all articles in a systematic manner and
to provide a standardised rating of each article offered as evi-
dence to support individual criteria. Rather, the articles were
provided as a reference repository to be accessed whenever
the expert panel members needed to check the supporting
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reference papers relating to particular proposed STOPP/
START criteria.
As with STOPP/START version 1, topics were chosen
for inclusion according to their considered importance
within each physiological system, provided they had a sound
evidence base, following literature search.
When the review of the ﬁrst draft of version 2 criteria was
complete, we sent the draft criteria to each member of the
expert panel for review and feedback. We used SurveyMonkey®
software to facilitate an online Delphi validation, an established
method of achieving consensus [9]. Using the Delphi validation
method, we presented each criterion to the expert panel
members in the form of a statement, e.g. Antipsychotics (i.e.
other than quetiapine or clozapine) in older patients with
Parkinsonism or Lewy Body Disease should be avoided due
to the risk of severe extra-pyramidal symptoms. Each expert
panel member then chose his/her level of agreement with
each statement, ranging from ‘strongly agree’ to ‘strongly
disagree’. Panellists were also given a ‘don’t know’ option and
had the opportunity to comment on each suggested criterion
using free text feedback before moving to the next proposed
criterion for evaluation.
A Likert scale was used to measure the responses:
0 = don’t know; 1 = strongly agree; 2 = agree; 3 = neutral;
4 = disagree; 5 = strongly disagree. The median and inter-
quartile range values were calculated for each response in
each iteration of the Delphi process. Criteria with a median
value of 1 or 2 and a 75th centile value of not >2 were
retained. Criteria with a higher median value were excluded.
Following the ﬁrst validation round, we removed any pro-
posed criteria that did not meet the retention requirements.
We then drew up the second draft of the new criteria and pro-
ceeded to a second round of Delphi validation, once again
using an online method, and inviting free text feedback from
panel members on each criterion. As in the ﬁrst validation
round, we excluded those criteria that did not meet the reten-
tion requirements detailed previously. We planned to continue
this process of repeated Delphi validation rounds until agree-
ment to retain or reject was reached on all proposed criteria
before declaring that the validation process was complete.
The construction and validation process of STOPP/
START version 2 is summarised as follows:
Phase 1: Call for review of STOPP/START version 1 cri-
teria and proposal of a new evidence-based cri-
teria/removal of obsolete criteria.
Phase 2: Draft 1 of STOPP/START version 2 criteria.
Phase 3: Search of PubMed, Embase and Cochrane data-
bases for systematic reviews, reviews and other refer-
ences to support STOPP/START version 2 criteria.
Phase 4: Draft 2 of STOPP/START version 2 criteria, with
support literature.
Phase 5: Delphi validation Round 1 (19 experts).
Phase 6: Draft 3 of STOPP/START version 2 criteria.
Phase 7: Delphi validation Round 2 (19 experts).
Phase 8: Draft 4 of STOPP/START version 2 criteria (ﬁnal
draft).
Results
For the ﬁrst expert panel consultation, there was a list of 138
proposed STOPP/START criteria for evaluation. These
included the original 87 STOPP/START version 1 criteria
plus 37 possible additional criteria proposed by the Irish
STOPP/START criteria group; we also received suggestions
for a further 14 criteria from the international expert review
panel. Of the 138 proposed criteria, 127 criteria had support-
ing published evidence sufﬁcient to warrant their inclusion in
Round 1 of the Delphi validation which yielded 124 criteria
with median Likert scores of 1 or 2. One hundred and seven
of these 124 criteria had median Likert scores with 75th
centile values of 1 or 2 and were retained as validated criteria.
The remaining 17 criteria (7 STOPP and 10 START criteria)
formed the basis for Delphi consensus Round 2 which
achieved consensus on 7 criteria; a third consensus validation
round was not required. The full list of references which sup-
ports the new STOPP criteria and START criteria is given in
Supplementary data, Appendices 1 and 2 and the ﬁnal list of
new STOPP criteria and the new START criteria is given in
Supplementary data, Appendices 3 and 4 available in Age and
Ageing online, respectively.
Fifteen of the criteria from STOPP/START version 1
were not included in STOPP/START version 2 (Table 1) on
the basis of a lack of sufﬁciently robust or consistent evi-
dence in the published literature [10]. Table 2 details those
criteria rejected during the Delphi consensus validation of
STOPP/START version 2.
Table 1. STOPP/START version 1 criteria removed from
the proposed version 2 because of weak or equivocal
supporting evidence
STOPP criteria
Aspirin with no history of coronary, cerebral or peripheral arterial occlusive
symptoms
Calcium channel blockers with chronic constipation
Non-cardioselective beta-blocker with chronic obstructive pulmonary disease
Use of aspirin and warfarin in combination without histamine H2 receptor
antagonist (except cimetidine because of interaction with warfarin) or proton
pump inhibitor
Dipyridamole as monotherapy for cardiovascular secondary prevention
Aspirin to treat dizziness not clearly attributable to cerebrovascular disease
Phenothiazines in patients with epilepsy
Diphenoxylate, loperamide or codeine phosphate for treatment of severe
gastroenteritis
Selective alpha-blockers in males with frequent urinary incontinence, i.e. one
or more episodes of incontinence daily
First-generation antihistamines in patients with falls
Long-term opioids in patients with falls
Long-term opioids in those with dementia unless indicated for palliative care
or management of moderate/severe chronic pain syndrome
START criteria
Metformin with type 2 diabetes mellitus +/−metabolic syndrome (in the
absence of renal impairment, i.e. serum creatinine > 150 μmol/l, or estimated
GFR < 50 ml/min/1.73 m2)
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus
Statin therapy for primary prevention of cardiovascular disease in diabetes
mellitus
GFR, glomerular filtration rate.
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Discussion
STOPP/START criteria are important for several reasons.
Since the ﬁrst iteration of STOPP/START in 2008, there
have been 74 published articles describing the use of
STOPP/START criteria in the PubMed database [http://
www.ncbi.nlm.nih.gov/pubmed/?term=stopp+criteria (14
November 2013, date last accessed)], including 5 review arti-
cles and 45 original research articles involving STOPP/
START criteria in various clinical scenarios. These publica-
tions originate from 24 countries. A recent Australian study
comparing Beers criteria, STOPP/START criteria and pre-
scribing indicators in Elderly Australians criteria concluded
that the number and scope of drug-related problems identi-
ﬁed by pharmacists was best represented by STOPP/
START criteria [11].
The fact that STOPP/START criteria have been success-
fully applied for both research and practical clinical purposes
in several countries in Europe, Asia, Australia, North
America and South America indicates that the criteria prob-
ably have true global relevance. The relevance of STOPP/
START criteria is further supported by the tangible clinical
beneﬁts demonstrated in the studies completed by our
group, alluded to in the Introduction.
Version 2 of STOPP/START, with 114 criteria, repre-
sents a 31% increase in the total number of criteria included
in version 1. This number of criteria may be considered un-
wieldy by some users, particularly those in busy clinical prac-
tice. Development of STOPP/START software applications
has opened up the real possibility of applying the criteria in
routine clinical practice globally.
Undoubtedly, some criteria have greater clinical import-
ance than others, and there may be an argument in favour of
hierarchical prioritisation within the overall set of STOPP/
START criteria. However, we considered that such hierarch-
ical prioritisation might introduce unnecessary complexity to
using STOPP/START, particularly when the criteria refer to
potential rather than absolute medication inappropriateness.
Inevitably, there will be comparisons between STOPP/
START version 2 and Beers criteria version 4 published in
2012 [12]. Although we have included a new section in
STOPP criteria containing three implicit prescribing rules,
STOPP/START, like Beers criteria, are essentially explicit
criteria for PIMs. However, some important essential differ-
ences between STOPP/START and Beers criteria remain,
principally the list of PPO’s (START criteria) and the avoid-
ance of mention of some Beers criteria drugs that are now
absent from most European drug formularies, e.g. guana-
benz, reserpine, mesoridazine, estazolam, trimethobenza-
mide and metaxalone.
In STOPP/START criteria, we decided not to indicate
the comparative clinical relevance/severity of each criterion,
since we considered almost all of the potential instances
of IP in STOPP and START lists to be non-trivial, i.e. poten-
tially serious.
There are several PIM criteria sets in the published litera-
ture [4].However, only ﬁve published studies describe the ap-
plication of PIM criteria as an intervention tool for improving
medication appropriateness [13–16]. Three of these ﬁve
studies describe the use of Beers criteria or variations of
Beers criteria [13–15], one study deals with inappropriate
prescribing in the elderly tool (IPET) criteria [16] and one
study with STOPP/START criteria [7]. In our opinion, only
those sets of PIM criteria that have tangible clinical beneﬁt
when applied as an intervention merit serious attention.
Three of these ﬁve intervention studies used either Beers cri-
teria or an adaptation of Beers criteria or IPET criteria as
both the intervention and the primary outcome measure
[13–15].Gill et al. [16] reported that 37.9% of PIMs identiﬁed
by IPET were discontinued by the prescribing physician, i.e.
the intervention and the outcome measure were essentially
the same. Although all ﬁve studies report beneﬁt, only the
study by Gallagher et al. [7] described an intervention (STOPP/
START criteria) that was distinct from the outcome measure
(Medication Appropriateness Index).
All explicit IP criteria essentially aim to improve medica-
tion appropriateness and/or avoid potentially serious ADRs
and ADEs. IP criteria are clinically relevant if they signiﬁ-
cantly reduce the rate of ADRs or ADEs when applied pro-
spectively to an unselected population of older patients in a
particular clinical setting. STOPP/START criteria meet this
essential requirement for clinical relevance on the basis of a
highly signiﬁcant reduction in ADR incidence in older hospi-
talised patients whose medication has been adjusted accord-
ing to STOPP/START criteria compared with similar older
patients receiving standard pharmaceutical care [8].
Table 2. Proposed criteria rejected by the expert panel for
inclusion in STOPP/START version 2 using Delphi
consensus
Rejected new STOPP criteria
Diuretic for treatment of hypertension with concurrent urinary incontinence
(may exacerbate incontinence)
SSRIs with concurrent bleeding diathesis, prescription of anticoagulants or
antiplatelet agents (increased risk of bleeding in general), active peptic ulcer
disease or concurrent NSAID prescription (risk of gastrointestinal bleeding)
SSRIs in patients with previous history of major non-traumatic bleeding or in
combination with drugs that may promote peptic ulceration, e.g. NSAIDs
(increased risk of recurrent major bleeding)
Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin
inhibitors or factor Xa inhibitors with concurrent high bleeding risk, i.e.
HAS-BLED score ≥3; HAS-BLED (hypertension, abnormal renal/liver
function, stroke, bleeding history, labile INRs, elderly (age > 65 years), drugs
that promote bleeding/alcohol)
Antidepressants of any kind in patients with recurrent falls
Rejected new START criteria
Memantine for moderate–severe Alzheimer’s disease
Dopamine agonist (e.g. ropinirole or pramipexole) for Restless Legs
Syndrome once iron deficiency has been excluded
Statin therapy in diabetes mellitus, unless the patient is at end of life or more
appropriate for palliation
Phosphodiesterase type-5 inhibitor with persistent erectile dysfunction
SSRI, selective serotonin reuptake inhibitor; NSAID, non-steroidal anti-
inflammatory drug.
While these criteria have a significant supportive evidence, the expert panel did
not judge them to be of such high importance as to be considered potentially
inappropriate in every case where they are encountered.
216
D. O’Mahony et al.
The present validation study shows the need to update
and revise explicit IP criteria on a regular basis. The total
number of STOPP/START criteria has increased by 31%
from version 1 to version 2 between 2008 and 2013. Most of
the extra criteria do not pertain to new drugs with new indi-
cations arriving on the market during that 5-year time inter-
val. Rather, they arise from new trial information, new
systematic reviews and expert panel suggestions for addi-
tional criteria.
Although there are research data to indicate that the ﬁrst
iteration of STOPP/START as an intervention has clinical
relevance in the acute hospital setting, it remains to be seen
whether STOPP/START version 2 offers further ADR/
ADE prevention beneﬁts to older patients in various clinical
settings. A recently funded European Commission Seventh
Framework Programme project, called SENATOR [http://
www.senator-project.eu (19 June 2014, date last accessed)],
will examine the efﬁcacy of a new pharmacotherapy opti-
misation software intervention based largely on STOPP/
START criteria. The primary outcome measure of the inter-
national multi-centre RCT designed to test SENATOR soft-
ware’s efﬁcacy will be ADR incidence in older people
hospitalised with acute illness.
Key points
• PIMs and PPOs are commonly encountered in older
people. PIMs and PPOs are closely related to ADEs and
ADRs, but they are preventable.
• STOPP/START criteria have been shown to be signiﬁcant-
ly associated with ADEs in acutely ill older people, unlike
Beers criteria.
• In single-centre RCTs, STOPP/START criteria used as an
intervention signiﬁcantly improve medication appropriate-
ness and reduce the incidence of ADRs in older people in
hospital, compared with standard pharmaceutical care.
• Since the ﬁrst publication of STOPP/START criteria in
2008, the therapeutics evidence base as it applies to older
people has expanded signiﬁcantly, indicating the need for
updating and revision of STOPP/START criteria. The
present study describes this process, resulting in a 31% in-
crease of the number of STOPP/START criteria compared
with the 2008 version, i.e. 114 criteria.
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Disclaimer (STOPP/START criteria
version 2)
Whilst every effort has been made to ensure that the poten-
tially inappropriate prescribing criteria listed in STOPP/
START version 2 are accurate and evidence-based, it is
emphasized that the ﬁnal decision to avoid or initiate any
drug referred to in these criteria rests entirely with the pre-
scriber. It is also to be noted that the evidence base under-
lying certain criteria in STOPP/START version 2 may
change after the time of publication of these criteria.
Therefore, it is advisable that prescribing decisions should
take account of current published evidence in support of or
against the use of drugs or drug classes described in
STOPP/START version 2 criteria.
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